VYNE Therapeutics Inc. logo

VYNE Therapeutics (VYNE) stock

VYNE · VYNE Therapeutics Inc. · NASDAQ

Website

What is the latest news on VYNE stock?

INSIDERago
Chief Development Officer Payton Lori was granted 99,827 stock options (SEC Form 4)

4 - Yarrow Bioscience, Inc. (0001566044) (Issuer)

All VYNE news

When does VYNE Therapeutics report earnings?

VYNE Therapeutics last reported on Nov 10, 2021, the date it announced on Oct 28, 2021. Before that it reported on Aug 12, 2021.

VYNE earnings history

Latest news

25 items
News · 26 weeks54+100%
2026-05-24: 02026-05-31: 22026-06-07: 02026-06-14: 22026-06-21: 02026-06-28: 42026-07-05: 32026-07-12: 22026-07-19: 82026-07-26: 172026-08-02: 32026-08-09: 32026-08-16: 12026-08-23: 02026-08-30: 02026-09-06: 32026-09-13: 12026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 52026-11-01: 02026-11-08: 02026-11-15: 0
2026-05-242026-11-15
Mix990d
  • Insider5(56%)
  • SEC Filings4(44%)
Activity · 52 weeks7936 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

VYNE Therapeutics Inc. (VYNE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for VYNE, including 5 insider trades. The most recent was published Oct 30, 2026.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

VYNE FAQ

7 questions
  • What does VYNE Therapeutics Inc. do?
    VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib...
  • Where does VYNE stock trade?
    VYNE Therapeutics Inc. (VYNE) is listed on NASDAQ.
  • What sector and industry is VYNE in?
    VYNE Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did VYNE Therapeutics Inc. go public?
    VYNE Therapeutics Inc. (VYNE) completed its IPO in 2018.
  • What are analysts saying about VYNE?
    Across the last 3 analyst actions on VYNE Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from BTIG Research: Neutral on 2025-07-31. Recent price targets range from $7.00 to $8.00.
  • What companies are similar to VYNE?
    Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare VYNE side-by-side with any of them on Quantisnow.
  • How can I track VYNE on Quantisnow?
    Quantisnow aggregates VYNE Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VYNE to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change